Breaking News
20 hours ago
Vaibhavi M.

Medicus Pharma files EU CTIS substantial modification to advance Teverelix Phase 2b in high cardiovascular-risk prostate cancer patients.
Vaibhavi M.

Tonix secures a second GPO agreement for TONMYA, bringing total U.S. commercial coverage to 52 million lives within 30 days of launch.
Vaibhavi M.

Eledon's tegoprubart achieved 100% insulin independence in all 12 islet transplant patients, with no rejection episodes and a calcineurin inhibitor-free protocol.
Vaibhavi M.

Maiva Pharma commissions a sterile injectables facility in Tamil Nadu, expanding capacity for generic and complex injectable products.
Vaibhavi M.
